首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2126533

多重檢測：市場洞察、競爭格局與市場預測 - 2034 年

Multiplex Assays - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年09月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

概述：

2025 年多重檢測市場規模估計為 41 億美元，預計到 2034 年將達到 93 億美元。這一成長是由高通量、多參數生物標記分析的快速普及、傳染病檢查中症候群特異性分子診斷的擴展以及蛋白質組學和精準腫瘤學研發投入的增加所推動的。
全球多重檢測市場預計在 2026 年至 2034 年的預測期內將以 9.5% 的複合年成長率成長。
按產品類型分類，試劑和耗材部分預計到 2025 年將佔市場佔有率的 66%，主導多重檢測市場。
按類型分類，預計到 2025 年，蛋白質多重檢測細分市場將佔 46% 的市場佔有率，從而推動多重檢測市場的發展。
按技術分類，多重免疫檢測領域預計將引領多重測定市場，到 2025 年將佔 28% 的市場佔有率。
按應用領域分類，預計到 2025 年，腫瘤學領域將佔 29% 的市場佔有率，從而推動多重檢測市場的發展。
預計到 2025 年，北美將以 40% 的銷售額主導全球多重檢測市場，在全球各地區中佔最高的市場佔有率。

多重檢測是一種分析技術，它能夠同時檢測和定量單一檢體中的多種分析物，例如蛋白質、核酸、細胞激素和生物標記。多重檢測取代了傳統的單分析物順序檢測（例如酵素連結免疫吸附試驗ELISA），實現了單一、高通量的工作流程。在現代生物醫學研究和診斷中，對複雜生物特徵的同時分析的需求日益成長，遠超單參數分析，這使得多重檢測成為藥物研發、臨床診斷和學術研究的重要工具。該市場按產品類型（儀器、試劑和耗材）、類別（基於細胞、蛋白質、核酸和其他多重檢測）和技術進行細分，技術包括多重即時PCR、流式細胞技術、多重免疫檢測、微陣列、質譜和其他平台。主要應用包括感染疾病診斷、腫瘤學、伴隨診斷、藥物發現和開發以及生物標記的發現和檢驗。終端用戶包括製藥和生物製藥公司、醫院和臨床檢查室以及學術和研究機構。在精準醫療興起、基於症候群的傳染病檢查不斷擴展以及對蛋白質組學和基因組學生物標記平台的巨額投資的推動下，多重檢測已成為支撐現代診斷和轉化研究的重要基礎。

多重檢測市場的主要成長促進因素

以微珠為基礎的多重平台在臨床和商業環境中的快速普及推動了市場需求，Luminex 的 xMAP 技術已被超過 105,000 篇同行評審論文引用，並在全球部署了超過 20,000 台設備。
基於症候群的多重檢測技術在傳染病檢查的應用日益廣泛，且發展速度正在加速。 2025年9月，QIAGEN的高通量QIAstat-Dx Rise系統獲得FDA核准。這是該公司今年獲得的第三個QIAstat-Dx系列產品批准，進一步擴大了該系列產品的部署規模，目前已在全球100多個國家擁有超過4600台設備。
Seegene公司專有的症候群即時PCR技術可在單一反應管中檢測多達14種不同的病原體，並以此為基礎向100多個國家供應了超過3.4億份新冠病毒檢測套組。隨後，該技術的應用範圍已擴展到具有重疊症狀的病原體的鑑別診斷，例如單純皰疹病毒（HSV）、水痘帶狀皰疹病毒（VZV）和痘病毒。
隨著製藥和生物技術領域研發投入的不斷增加，尤其是在蛋白質體學和生物標記發現方面，對自動化多重免疫檢測平台（例如Bio-Techne公司的Simple Plex Ella系統）的需求也在不斷成長。該系統可在90分鐘內對每個檢體中的多達8種分析物進行定量分析，其測量菜單涵蓋超過350個目標。
診斷設備製造商報告稱，其多重檢測產品系列持續保持兩位數成長。 Revvity 的診斷部門在 2025 年第四季銷售額成長了 10%，其中 7% 的內部成長，這證實了市場對免疫診斷和多重檢測平台的需求不斷成長。
策略整合正在拓展整個價值鏈的多重偵測能力。 DiaSorin 以 18 億美元收購 Luminex 公司就是一個典型的例子。此次收購將 DiaSorin 的診斷業務與 Luminex 的多重檢測技術相結合，擴大了其在生命科學領域的業務範圍。
精準醫療、症候群檢測的擴展、生物標記主導的藥物發現以及平台整合的結合，預計將推動多重檢測市場在 2034 年前實現強勁成長。

推動多重檢測市場成長的因素

市場促進因素

多重免疫檢測和以微珠為基礎的平台的應用日益廣泛

多重檢測市場最主要的促進因素是以微珠為基礎和微流體技術的多重免疫檢測平台在生物標記研究中的廣泛應用。例如，Luminex 的 xMAP 技術等以微珠為基礎的平台，以及 Bio-Rad 的 Bio-Plex Pro 系列和 Bio-Techne 的 Simple Plex Ella 系統等基於試劑盒的系統，使研究人員能夠從少量單樣本中分析細胞激素、趨化素和疾病生物標記，從而用單一的多重檢測流程取代多次連續的 ELISA 檢測。僅 Luminex xMAP 技術就已被超過 105,000 篇同行評審的研究論文引用，並且在全球部署了超過 20,000 台設備，其在學術機構、製藥公司和臨床檢查室中的廣泛應用顯而易見。隨著生物標記組合日益複雜，檢查室致力於減少檢體量和縮短檢測週期，對多重免疫檢測平台及其相關試劑的需求持續成長，這將為 2034 年前的市場成長奠定基礎。

基於症候群的連接複用技術的擴展

基於症候群的多分子診斷技術在傳染病檢查的快速發展是推動市場擴張的強大動力。 QIAGEN 的 QIAstat-Dx 平台和 Seegene 的 Allplex 檢測等系統能夠利用基於 PCR 的即時檢測技術同時檢測多種引起重疊臨床症狀的病原體，從而提高診斷準確性並減少不必要的抗生素使用。 2025 年 9 月，QIAGEN 的高通量 QIAstat-Dx Rise 系統獲得 FDA 批准。這是該公司當年第三款獲批的 QIAstat-Dx 產品，進一步擴大了其在全球 100 多個國家和地區的部署規模，累計設備超過 4600 台。同時，Seegene 的症候群特異性即時PCR技術可在單一試管中檢測多達 14 種病原體，並被應用於區分具有重疊症狀的疾病，例如單純皰疹病毒 (HSV)、水痘-帶狀皰疹病毒 (VZV) 和痘病毒。隨著呼吸道疾病、消化器官系統疾病和新興感染疾病的檢測數量增加，醫院和實驗室擴大轉向使用針對特定症候群的多重檢測來取代單靶點檢測。

市場限制因素

儘管多重檢測市場發展勢頭強勁，但仍面臨諸多限制因素。多重分析儀的高昂初始成本，以及專用試劑盒和檢測板的持續投入，都阻礙了小規模檢查室和價格敏感型市場採用此技術。驗證高通量檢測板在技術上極具挑戰性，需要精心設計檢測方法並進行嚴格的品管，因為檢驗數量的增加會同時提高交叉反應、訊號干擾和單一標靶靈敏度降低的風險。多重診斷檢測板的法規核准流程複雜，因為每個新的病原體或生物標記標靶通常都需要單獨的核准或檢驗，這導致開發週期延長和成本增加。新型多重診斷檢測板的保險覆蓋率和採用率在不同地區仍存在差異，而受過多重檢測開發、生物資訊學和數據解讀培訓的專業人員短缺也限制了業務規模的擴大。此外，多重資料集日益複雜，也為檢查室的資訊科學和資料管理帶來了更大的負擔。這些成本、技術、監管和人才方面的障礙，共同減緩了市場的成長速度。另一方面，精準醫療、症候群檢測的擴展以及生物標記主導的藥物發現等基本促進因素仍然強勁。

多重檢測市場：市場促進因素
- 多重免疫檢測和以微珠為基礎的平台擴展
- 基於症候群的多重分子診斷的擴展
- 增加對蛋白質體學和精準腫瘤學的投資
- 策略整合與平台整合
多重檢測市場：限制因素與挑戰
- 高成本和持續的試劑成本
- 高分子麵板的技術複雜性和交叉反應性
- 法規、人員和資料管理的複雜性。
多重檢測市場：市場機遇
- 人工智慧驅動的檢測設計和自動化
- 新興市場和現場檢查的擴展

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

美國
歐洲
日本
中國

第6章：波特五力分析

第7章：多重檢測市場評估

依產品類型
- 裝置
- 試劑和耗材
按類型
- 基於細胞的多重檢測
- 蛋白質多重檢測
- 核酸多重檢測
- 其他
透過技術
- 多重即時PCR
- 流式細胞技術
- 多重免疫檢測
- 微陣列
- 質譜分析
用途別
- 感染疾病診斷
- 腫瘤學
- 伴隨診斷
- 藥物發現與開發
- 生物標記的發現與檢驗
最終用戶
- 製藥和生物製藥公司
- 醫院和臨床檢查室
- 學術研究機構
按地區
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第8章：多重偵測市場：競爭格局

市場集中度與結構
競爭定位與市場佔有率分析（加值服務）

第9章多重檢測市場：新創企業資金籌措與投資趨勢

第10章：多重檢測市場：公司概況與產品概況

Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
DiaSorin SpA（Luminex）
QIAGEN NV
Illumina, Inc.
Merck KGaA
Becton, Dickinson and Company（BD）
Revvity, Inc.
Bio-Techne Corporation
Seegene Inc.

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章免責聲明與聯絡方式

簡介目錄圖表

Product Code: DIMDCL0997

Multiplex Assays Market Summary

Overview:

The Multiplex Assays market is estimated at USD 4.10 billion in 2025 and is projected to reach USD 9.30 billion by 2034. Growth is anchored in the rapid adoption of high-throughput, multi-analyte biomarker profiling, the expansion of syndromic molecular diagnostics for infectious disease testing, and rising R&D investment in proteomics and precision oncology.
The global Multiplex Assays market is growing at a CAGR of 9.5% during the forecast period from 2026 to 2034.
By product type, the reagents & consumables segment dominated the Multiplex Assays market with a 66% share in 2025.
By type, the protein multiplex assays segment dominated the Multiplex Assays market with a 46% share in 2025.
By technology, the multiplex immunoassays segment dominated the Multiplex Assays market with a 28% share in 2025.
By application, the oncology segment dominated the Multiplex Assays market with a 29% share in 2025.
North America dominated the global Multiplex Assays market revenue with a 40% share in 2025, representing the highest regional market share globally.

A multiplex assay is an analytical technique that enables the simultaneous detection and quantification of multiple analytes, such as proteins, nucleic acids, cytokines, and biomarkers, within a single sample, replacing sequential single-analyte tests such as conventional ELISA with a single, high-throughput workflow. Because modern biomedical research and diagnostics increasingly demand simultaneous profiling of complex biological signatures rather than single-parameter analysis, multiplex assays have become foundational tools across pharmaceutical R&D, clinical diagnostics, and academic research. The market is organized by product type across instruments and reagents & consumables; by type, spanning cell-based, protein, nucleic acid, and other multiplex assays; by technology, including multiplex real-time PCR, flow cytometry, multiplex immunoassays, microarray, mass spectrometry, and other platforms; by application, led by infectious disease diagnostics, oncology, companion diagnostics, drug discovery & development, and biomarker discovery & validation; and by end-user, spanning pharmaceutical and biopharmaceutical companies, hospitals and clinical laboratories, and academic and research institutes. Driven by the rise of precision medicine, the expansion of syndromic infectious disease testing, and heavy investment in proteomic and genomic biomarker platforms, multiplex assays have become essential infrastructure underpinning modern diagnostics and translational research.

Multiplex Assays Market Key Growth Drivers

The rapid clinical and commercial adoption of bead-based multiplexing platforms is driving demand, with Luminex xMAP Technology cited in more than 105,000 peer-reviewed studies and supporting a worldwide installed base exceeding 20,000 instruments.
The expansion of syndromic multiplex molecular diagnostics for infectious disease testing is accelerating adoption, with QIAGEN securing FDA clearance for its higher-throughput QIAstat-Dx Rise system in September 2025, its third QIAstat-Dx clearance of the year, extending an installed base of over 4,600 instruments across more than 100 countries.
Seegene's proprietary syndromic real-time PCR technology, capable of detecting up to 14 pathogens in a single reaction tube, underpinned the supply of more than 340 million COVID-19 tests to over 100 countries and has since been extended to differential diagnosis of overlapping pathogens such as HSV, VZV, and mpox virus.
Rising pharmaceutical and biotechnology R&D investment in proteomics and biomarker discovery is expanding demand for automated multiplex immunoassay platforms, such as Bio-Techne's Simple Plex Ella system, which quantifies up to eight analytes per sample in under 90 minutes across a menu of more than 350 targets.
Diagnostics companies are reporting sustained double-digit growth in multiplex-enabled portfolios; Revvity's diagnostics segment posted 10% fourth-quarter revenue growth in 2025, with 7% organic growth, reinforcing demand for immunodiagnostic and multiplex testing platforms.
Strategic consolidation is expanding multiplexing capability across the value chain, exemplified by DiaSorin's USD 1.8 billion acquisition of Luminex Corporation, which combined DiaSorin's diagnostics footprint with Luminex's multiplexing technology and expanded life-science reach.
The convergence of precision medicine, syndromic testing expansion, biomarker-driven drug development, and platform consolidation is expected to sustain strong growth in the multiplex assays market through 2034.

Key Companies in Multiplex Assays Market

The competitive landscape is led by the following active manufacturers:

Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
DiaSorin S.p.A. (Luminex)
QIAGEN N.V.
Illumina, Inc.
Merck KGaA
Becton, Dickinson and Company (BD)
Revvity, Inc.
Bio-Techne Corporation
Seegene Inc.

Factors Contributing to the Growth of the Multiplex Assays Market

Market Drivers

Expanding Adoption of Multiplex Immunoassay and Bead-Based Platforms

The most established driver of the Multiplex Assays market is the broad adoption of bead-based and microfluidic multiplex immunoassay platforms across biomarker research. Bead-based platforms such as Luminex xMAP Technology and panel-based systems such as Bio-Rad's Bio-Plex Pro portfolio and Bio-Techne's Simple Plex Ella system allow researchers to profile cytokines, chemokines, and disease biomarkers from a single low-volume sample, replacing many sequential ELISA runs with one multiplexed workflow. Luminex xMAP Technology alone has been cited in more than 105,000 peer-reviewed studies and supports a worldwide installed base exceeding 20,000 instruments, underscoring the depth of adoption across academic, pharmaceutical, and clinical laboratories. As biomarker panels grow in complexity and laboratories seek to conserve sample volume and turnaround time, demand for multiplex immunoassay platforms and their associated reagent menus continues to expand, anchoring market growth through 2034.

Expansion of Syndromic Multiplex Molecular Diagnostics

The rapid growth of syndromic, multiplex molecular diagnostics for infectious disease testing is a powerful driver of market expansion. Systems such as QIAGEN's QIAstat-Dx platform and Seegene's Allplex assays enable simultaneous, real-time PCR-based detection of multiple pathogens that cause overlapping clinical symptoms, improving diagnostic accuracy while reducing unnecessary antibiotic use. QIAGEN received FDA clearance for its higher-throughput QIAstat-Dx Rise system in September 2025, its third QIAstat-Dx clearance that year, extending an installed base of more than 4,600 instruments across over 100 countries, while Seegene's syndromic real-time PCR technology, capable of detecting up to 14 pathogens in a single tube, has been adapted to differentiate overlapping conditions such as HSV, VZV, and mpox virus. As respiratory, gastrointestinal, and emerging infectious disease testing volumes rise, syndromic multiplex panels are increasingly displacing single-target assays across hospital and reference laboratories.

Market Restraints

Despite strong momentum, the Multiplex Assays market faces material constraints. The high upfront cost of multiplexing instruments and the recurring cost of proprietary reagent cartridges and panels create adoption barriers for smaller laboratories and price-sensitive markets. Highly multiplexed panels can be technically challenging to validate, as increasing the number of simultaneously measured analytes raises the risk of cross-reactivity, signal interference, and reduced sensitivity for individual targets, requiring careful assay design and rigorous quality control. Regulatory pathways for multiplex diagnostic panels are complex, since each new pathogen or biomarker target typically requires separate clearance or validation, lengthening development timelines and raising costs. Reimbursement and adoption of newer multiplex diagnostic panels remain uneven across geographies, and the shortage of skilled personnel trained in multiplex assay development, bioinformatics, and data interpretation constrains scale-up. The growing complexity of multiplex datasets also raises the informatics and data-management burden on laboratories. Together, these cost, technical, regulatory, and workforce barriers temper the pace of growth, even as the underlying drivers of precision medicine, syndromic testing expansion, and biomarker-driven drug development remain firmly intact.

Multiplex Assays Market Segment Analysis

The multiplex assays market by product type (instruments, reagents & consumables), type (cell-based multiplex assays, protein multiplex assays, nucleic acid multiplex assays, others), technology (multiplex real-time pcr, flow cytometry, multiplex immunoassays, microarray, mass spectrometry, others), application (infectious disease diagnostics, oncology, companion diagnostics, drug discovery & development, biomarker discovery & validation, others), end-users (pharmaceutical & biopharmaceutical companies, hospitals & clinical laboratories, academic & research institutes, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Reagents & Consumables.

The reagents & consumables segment accounted for 66% of the Multiplex Assays market in 2025. Reagents and consumables lead because every multiplex run consumes proprietary assay kits, cartridges, beads, and panels, creating a recurring, high-frequency revenue stream that compounds with the growing installed base of multiplex instruments, mirroring the razor-and-blade model that underpins platforms such as Bio-Rad's Bio-Plex Pro panels, Luminex xMAP kits, and Bio-Techne's Simple Plex cartridges. As laboratories expand the breadth of biomarker and pathogen panels they run and as syndromic testing volumes rise, consumable demand scales directly with usage rather than one-time capital purchases. Instruments remain essential as the enabling capital investment and are important for placing new multiplex platforms into laboratories, but the sheer frequency and volume of consumable purchases across research, clinical, and pharmaceutical settings secure the segment's clear leadership across the forecast period.

By Type

Dominant Subsegment: Protein Multiplex Assays.

The protein multiplex assays segment accounted for 46% of the Multiplex Assays market in 2025. Protein-based multiplex assays lead because cytokine, chemokine, and biomarker profiling remains the most established and widely adopted multiplexing application, supported by mature bead-based and microfluidic immunoassay platforms such as Luminex xMAP, Bio-Rad's Bio-Plex Pro portfolio, and Bio-Techne's Simple Plex Ella system, which together offer menus spanning hundreds of validated protein targets. The established analytical performance, broad target menus, and deep integration of protein multiplexing into immunology, oncology, and cardiovascular research sustain great and dependable demand. Nucleic acid multiplex assays are the fastest-growing type, propelled by the expansion of syndromic multiplex PCR testing for infectious disease, while cell-based multiplex assays are gaining traction in immune-monitoring and cell therapy quality control. Nonetheless, the breadth and maturity of the protein multiplexing ecosystem secure its leadership across the forecast period.

Multiplex Assays Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Multiplex Assays market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature life-science research ecosystem, deep clinical-diagnostics infrastructure, and the concentration of leading multiplex platform providers, including Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina, and Bio-Techne, headquartered in the United States. North America hosts the largest base of academic and pharmaceutical R&D spending on biomarker discovery and companion diagnostics, and sponsors benefit from clear FDA regulatory pathways that have supported a wave of syndromic multiplex diagnostic clearances, including QIAGEN's QIAstat-Dx family. The commercial strength of multiplex immunoassay and molecular diagnostic platforms, combined with a deep clinical-research pipeline and rising precision-oncology adoption, drives substantial demand across instruments and consumables. Strong reimbursement pathways, regulatory clarity, and proximity to leading platform developers anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Multiplex Assays market. The region's elevated CAGR is driven by rapidly expanding biopharmaceutical R&D investment, growing genomics and proteomics research capacity, and rising healthcare infrastructure spending across China, Japan, India, South Korea, and Australia. China is scaling domestic molecular diagnostics manufacturing and biomarker research capacity, Japan is expanding precision oncology and companion diagnostics adoption, India is emerging as a lower-cost hub for clinical research and diagnostic testing, and South Korea benefits from strong domestic multiplex molecular diagnostics leadership through Seegene. Government healthcare investment, expanding infectious disease surveillance programs, and growing biomarker-driven drug development activity are accelerating adoption across the region. The combination of rising disease burden, infrastructure build-out, and expanding local manufacturing capability positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Multiplex Assays market revenue in 2025. The United States dominates on the strength of its life-science research infrastructure, deep clinical-diagnostics base, FDA regulatory clarity, and the concentration of leading multiplex platform developers, while sustained R&D investment in proteomics and precision oncology, and steady clearance of new syndromic diagnostic panels, reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by a strong diagnostics and life-science industrial base exemplified by DiaSorin in Italy, QIAGEN in Germany and the Netherlands, and Merck KGaA in Germany, alongside established EMA regulatory frameworks and collaborative academic research networks. Continued expansion of syndromic multiplex panel menus and growing biomarker research investment reinforce the region's role in supplying both diagnostic and research multiplex platforms across Germany, the United Kingdom, France, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by expanding biopharmaceutical R&D investment, growing genomics and proteomics research capacity, and rising healthcare infrastructure spending across China, Japan, India, South Korea, and Australia. China's expanding domestic diagnostics manufacturing, Japan's precision oncology adoption, India's growing clinical research base, and South Korea's multiplex molecular diagnostics leadership through Seegene are accelerating regional market growth.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding clinical laboratory and healthcare infrastructure, rising demand for infectious disease surveillance and precision diagnostics, and efforts to align regulatory frameworks with global standards are gradually broadening access, while international partnerships and technology transfer support the build-out of regional multiplex testing capacity.

Multiplex Assays Market Competitive Landscape

The Multiplex Assays market is classified as Moderately Consolidated. A group of integrated, multi-platform life-science and diagnostics leaders, including Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin (Luminex), QIAGEN, Illumina, Merck KGaA, and Becton Dickinson and Company, anchor the top tier through broad instrument and reagent portfolios and global commercial reach, while specialized and fast-scaling providers such as Revvity, Bio-Techne, and Seegene compete through focused platform innovation, deep reagent menus, and regional molecular-diagnostics leadership, increasing competition in the fastest-growing syndromic and biomarker-profiling segments.

The competitive landscape can be evaluated across the following dimensions:

Market concentration: Moderately consolidated, with integrated, multi-platform life-science and diagnostics leaders anchoring the top tier alongside a fast-growing field of specialized multiplex platform providers.
Leading players: Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin (Luminex), and QIAGEN anchor the top tier through broad instrument and reagent portfolios and global regulatory clearances.
Geographic reach: Leaders operate global, regionally distributed commercial and manufacturing networks; QIAGEN's QIAstat-Dx platform alone is available in more than 100 countries with over 4,600 instruments placed worldwide.
Product portfolio strength: Top players offer end-to-end multiplex solutions spanning instruments, reagent kits, software, and bioinformatics support across research and clinical applications.
Technology access: Ownership of proprietary multiplexing chemistries and detection platforms, including xMAP bead-based technology and automated microfluidic immunoassay systems, is a decisive competitive advantage.
Strategic partnerships: Collaborations with technology and publishing partners, such as Seegene's alliance with Microsoft and Springer Nature to expand global access to multiplex PCR testing, extend reach and accelerate innovation.
M&A activity: Active consolidation, including DiaSorin's USD 1.8 billion acquisition of Luminex Corporation and Thermo Fisher's acquisition of Olink, has broadened multiplexing capability across the industry.
Manufacturing capabilities: Automated cartridge and bead-based manufacturing, high-throughput reagent production, and quality-controlled antibody and probe development are key competitive moats.
Innovation focus: AI-enabled assay design, expanding syndromic panel menus, automated microfluidic immunoassay platforms, and spatial and single-cell multiplexing represent the leading edge of innovation.

Multiplex Assays Market Recent Developmental Activities

In September 2025, QIAGEN N.V. received FDA clearance for QIAstat-Dx Rise, a higher-throughput version of its automated syndromic testing system capable of processing up to 160 samples per day. Strategic significance: Marks QIAGEN's third FDA clearance for the QIAstat-Dx family in 2025 and extends an installed base exceeding 4,600 instruments across more than 100 countries.

In 2025, QIAGEN N.V. expanded its QIAstat-Dx panel menu with additional respiratory and gastrointestinal offerings, building on six FDA-cleared panels across the QIAstat-Dx family over twelve months. Strategic significance: Broadens QIAGEN's syndromic testing menu and reinforces its position in multiplex molecular diagnostics.

Multiplex Assays Market Segmentation

Multiplex Assays Market by Product Type

Instruments
Reagents & Consumables

Multiplex Assays Market by Type

Cell-Based Multiplex Assays
Protein Multiplex Assays
Nucleic Acid Multiplex Assays
Others

Multiplex Assays Market by Technology

Multiplex Real-Time PCR
Flow Cytometry
Multiplex Immunoassays
Microarray
Mass Spectrometry
Others

Multiplex Assays Market by Application

Infectious Disease Diagnostics
Oncology
Companion Diagnostics
Drug Discovery & Development
Biomarker Discovery & Validation
Others

Multiplex Assays Market by End-Users

Pharmaceutical & Biopharmaceutical Companies
Hospitals & Clinical Laboratories
Academic & Research Institutes
Others

Multiplex Assays Market by Geography

North America Multiplex Assays Market
United States Multiplex Assays Market Size in USD million (2023-2034)
Canada Multiplex Assays Market Size in USD million (2023-2034)
Mexico Multiplex Assays Market Size in USD million (2023-2034)
Europe Multiplex Assays Market
Germany Multiplex Assays Market Size in USD million (2023-2034)
United Kingdom Multiplex Assays Market Size in USD million (2023-2034)
France Multiplex Assays Market Size in USD million (2023-2034)
Italy Multiplex Assays Market Size in USD million (2023-2034)
Spain Multiplex Assays Market Size in USD million (2023-2034)
Rest of Europe Multiplex Assays Market Size in USD million (2023-2034)
Asia-Pacific Multiplex Assays Market
China Multiplex Assays Market Size in USD million (2023-2034)
Japan Multiplex Assays Market Size in USD million (2023-2034)
India Multiplex Assays Market Size in USD million (2023-2034)
Australia Multiplex Assays Market Size in USD million (2023-2034)
South Korea Multiplex Assays Market Size in USD million (2023-2034)
Rest of Asia-Pacific Multiplex Assays Market Size in USD million (2023-2034)
Rest of the World (RoW) Multiplex Assays Market
Middle East Multiplex Assays Market Size in USD million (2023-2034)
Africa Multiplex Assays Market Size in USD million (2023-2034)
South America Multiplex Assays Market Size in USD million (2023-2034)

Key Takeaways from the Multiplex Assays Market Report Study

Market size analysis for the current Multiplex Assays market size (2025), and market forecast for 9 years (2026 to 2034).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
Key companies dominating the global Multiplex Assays market.
Various opportunities available for competitors in the Multiplex Assays market space.
What are the top-performing segments in 2025? How will these segments perform in 2034?
Which are the top-performing regions and countries in the current Multiplex Assays market scenario?
Which are the regions and countries where companies should concentrate their opportunities for Multiplex Assays market growth in the future?

Target audience who can benefit from this Multiplex Assays market report study

Multiplex Assays product providers
Research organizations and consulting companies
Multiplex Assays -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in Multiplex Assays
Various end-users who want to know more about the Multiplex Assays market and the latest technological developments in the Multiplex Assays market.

Frequently Asked Questions:

Q1. What is the growth rate of the Multiplex Assays market?

The Multiplex Assays market is projected to expand at a CAGR of 9.5% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Multiplex Assays market?

The Multiplex Assays market is estimated at USD 4.10 billion in 2025 and is projected to reach USD 9.30 billion by 2034.

Q3. Which region dominates the Multiplex Assays market?

North America dominated the Multiplex Assays market with a 40% share of global revenue in 2025, supported by a mature life-science research ecosystem, deep clinical-diagnostics infrastructure, FDA regulatory clarity, and the concentration of leading multiplex platform providers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Multiplex Assays market?

The principal drivers are the expanding adoption of bead-based and immunoassay multiplexing platforms, exemplified by Luminex xMAP Technology's citation in more than 105,000 peer-reviewed studies; the rapid growth of syndromic multiplex molecular diagnostics for infectious disease testing, led by QIAGEN's QIAstat-Dx and Seegene's Allplex platforms; rising pharmaceutical investment in proteomics and precision-oncology biomarker discovery; and continued strategic consolidation among leading platform providers.

Q5. Who are the major players in the Multiplex Assays market?

The major players include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., DiaSorin S.p.A. (Luminex), QIAGEN N.V., Illumina, Inc., Merck KGaA, Becton, Dickinson and Company (BD), Revvity, Inc., Bio-Techne Corporation, and Seegene Inc., among other active providers profiled in the Competitive Landscape section, along with Quanterix Corporation, Standard BioTools (Akoya Biosciences), and Meso Scale Diagnostics, LLC. Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin, and QIAGEN lead through broad platform portfolios and global regulatory reach.

1. Multiplex Assays Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. Multiplex Assays Market Executive Summary

2.1 Market at a Glance

3. Multiplex Assays Market Key Factors Analysis

3.1 Multiplex Assays Market Drivers
- 3.1.1 Expansion of Multiplex Immunoassay and Bead-Based Platforms
- 3.1.2 Expansion of Syndromic Multiplex Molecular Diagnostics
- 3.1.3 Rising Investment in Proteomics and Precision Oncology
- 3.1.4 Strategic Consolidation and Platform Integration
3.2 Multiplex Assays Market Restraints and Challenges
- 3.2.1 High Instrument and Recurring Reagent Costs
- 3.2.2 Technical Complexity and Cross-Reactivity in High-Plex Panels
- 3.2.3 Regulatory, Workforce, and Data-Management Complexity
3.3 Multiplex Assays Market Opportunities
- 3.3.1 AI-Enabled Assay Design and Automation
- 3.3.2 Emerging-Market and Point-of-Need Testing Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. Multiplex Assays Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Multiplex Assays Market Assessment

7.1 By Product Type
- 7.1.1 Instruments
- 7.1.2 Reagents & Consumables
7.2 By Type
- 7.2.1 Cell-Based Multiplex Assays
- 7.2.2 Protein Multiplex Assays
- 7.2.3 Nucleic Acid Multiplex Assays
- 7.2.4 Others
7.3 By Technology
- 7.3.1 Multiplex Real-Time PCR
- 7.3.2 Flow Cytometry
- 7.3.3 Multiplex Immunoassays
- 7.3.4 Microarray
- 7.3.5 Mass Spectrometry
- 7.3.6 Others
7.4 By Application
- 7.4.1 Infectious Disease Diagnostics
- 7.4.2 Oncology
- 7.4.3 Companion Diagnostics
- 7.4.4 Drug Discovery & Development
- 7.4.5 Biomarker Discovery & Validation
- 7.4.6 Others
7.5 By End-Users
- 7.5.1 Pharmaceutical & Biopharmaceutical Companies
- 7.5.2 Hospitals & Clinical Laboratories
- 7.5.3 Academic & Research Institutes
- 7.5.4 Others
7.6 By Geography
- 7.6.1 North America
  - 7.6.1.1 United States Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.1.2 Canada Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.1.3 Mexico Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.2 Europe
  - 7.6.2.1 Germany Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.2.2 United Kingdom Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.2.3 France Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.2.4 Italy Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.2.5 Spain Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.2.6 Rest of Europe Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
  - 7.6.3.1 China Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.3.2 Japan Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.3.3 India Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.3.4 Australia Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.3.5 South Korea Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.3.6 Rest of Asia-Pacific Multiplex Assays Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
  - 7.6.4.1 Middle East Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.4.2 Africa Multiplex Assays Market Size in USD million (2023-2034)
  - 7.6.4.3 South America Multiplex Assays Market Size in USD million (2023-2034)

8. Multiplex Assays Market Competitive Landscape

8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Multiplex Assays Market Startup Funding and Investment Trends

10. Multiplex Assays Market Company and Product Profiles

10.1 Thermo Fisher Scientific, Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
10.2 Bio-Rad Laboratories, Inc.
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
10.3 DiaSorin S.p.A. (Luminex)
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
10.4 QIAGEN N.V.
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
10.5 Illumina, Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
10.6 Merck KGaA
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
10.7 Becton, Dickinson and Company (BD)
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
10.8 Revvity, Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
10.9 Bio-Techne Corporation
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10.10 Seegene Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.